Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
12 2019
Historique:
received: 26 02 2019
revised: 19 04 2019
accepted: 24 04 2019
pubmed: 12 5 2019
medline: 12 2 2020
entrez: 12 5 2019
Statut: ppublish

Résumé

We evaluated the characteristics of HIV-1 molecular transmission clusters (MTCs) in 1890 newly diagnosed individuals infected with non-B subtypes between 2005 and 2017 in Italy. Phylogenetic analyses were performed on 145 MTCs were identified and involved 666 individuals (35.2%); 319 of them (16.9%) were included in 13 LMTCs, 111 (5.9%) in 20 MMTCs and 236 (12.5%) in 112 SMTCs. Compared with individuals out of MTCs, individuals involved in MTCs were prevalently Italian (72.7% vs 30.9%, p<0.001), male (82.9% vs 62.3%, p<0.001) and men who have sex with men (MSM) (43.5% vs 14.5%, p<0.001). Individuals in MTCs were also younger (median (IQR) years: 41 (35-49) vs 43 (36-51), p<0.001) and had higher CD4 cell count in comparison with individuals out of MTCs (median (IQR): 10 Our findings show that HIV-1 newly diagnosed individuals infected with non-B subtypes are involved in several MTCs in Italy. These MTCs include mainly Italians and MSM and highlight the complex phenomenon characterising the HIV-1 spread. This is important especially in view of monitoring the HIV epidemic and guiding the public health response.

Identifiants

pubmed: 31076456
pii: sextrans-2019-054017
doi: 10.1136/sextrans-2019-054017
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-625

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Lavinia Fabeni (L)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy lavinia.fabeni@gmail.com.

Claudia Alteri (C)

Oncology and Oncohematology, University of Milan, Milan, Italy.

Giulia Berno (G)

Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Rossana Scutari (R)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Nicoletta Orchi (N)

AIDS Reference Center, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Gabriella De Carli (G)

AIDS Reference Center, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Ada Bertoli (A)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Luca Carioti (L)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Caterina Gori (C)

Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Federica Forbici (F)

Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Romina Salpini (R)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Alessandra Vergori (A)

Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Roberta Gagliardini (R)

Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Stefania Cicalini (S)

Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Annalisa Mondi (A)

Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Carmela Pinnetti (C)

Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Laura Mazzuti (L)

Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.

Ombretta Turriziani (O)

Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.

Manuela Colafigli (M)

Infectious Dermatology, San Gallicano-IRCCS, Rome, Italy.

Vanni Borghi (V)

Infectious Diseases, University Hospital of Modena, Modena, Italy.

Francesco Montella (F)

Infectious Diseases, S Giovanni Addolorata Hospital, Rome, Italy.

Alfredo Pennica (A)

Infectious Diseases, S Andrea Hospital, Rome, Italy.

Miriam Lichtner (M)

Infectious Diseases Unit, "Sapienza" University, Polo Pontino, Latina, Italy.

Enrico Girardi (E)

Clinical Epidemiology, INMI "Lazzaro Spallanzani" IRCCS, Rome, Lazio, Italy.

Massimo Andreoni (M)

Infectious Diseases, University Hospital "Tor Vergata", Rome, Italy.

Cristina Mussini (C)

Infectious Diseases, University Hospital of Modena, Modena, Italy.

Andrea Antinori (A)

Clinical Department, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Francesca Ceccherini-Silberstein (F)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Carlo Federico Perno (CF)

Oncology and Oncohematology, University of Milan, Milan, Italy.
Laboratory of Virology, INMI "Lazzaro Spallanzani"-IRCCS, Rome, Italy.

Maria Mercedes Santoro (MM)

Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH